Reuters logo
BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer
2017年9月7日 / 晚上10点28分 / 16 天前

BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

Sept 8 (Reuters) - Kura Oncology Inc

* Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

* Says ‍phase 2 trial for Tipifarnib​ achieved its primary endpoint prior to completion of enrollment

* Says ‍it will continue to enroll HRAS mutant HNSCC patients​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below